ATR/Chk1 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,686 results for “ATR/Chk1”

Circle Pharma to Reveal Dual Mechanism of Novel Cyclin A/B RxL Inhibitors at AACR 2025

CytoSorbents' DrugSorb-ATR Receives FDA Priority Review for Bleeding Reduction in Heart Surgery

Acrivon Therapeutics Reports 44% Response Rate for CHK1/2 Inhibitor ACR-368 in Endometrial Cancer Phase II Trial

Rakovina Therapeutics Presents AI-Discovered CNS-Penetrant ATR/mTOR Dual Inhibitors at Neuro-Oncology Meeting

FDA Denies CytoSorbents' De Novo Request for DrugSorb-ATR Blood Purification Device

Atrogi Doses First Patients in Phase 1 Trial of Exercise-Mimicking Drug ATR-258

Azitra's ATR-04 Receives FDA Fast Track Designation for EGFRi-Associated Skin Rash

Aprea Therapeutics Expands Global Patent Portfolio for WEE1 and ATR Precision Oncology Programs

Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers

Repare Therapeutics' ATR Inhibitor Camonsertib Shows Promise in DNA Repair-Deficient Cancers

Page 1 of 191